Glymphatic System Research Explodes 10x in 5 Years as Alzheimer's Link Crystallizes

Alzheimer's disease affects more than 50 million people globally and remains the sixth leading cause of death, yet disease-modifying therapies remain limited. A key emerging insight is that the glymphatic system — a brain-wide waste clearance network driven by cerebrospinal fluid (CSF) flow through perivascular spaces and regulated by Aquaporin-4 (AQP4) water channels at astrocytic endfeet — plays a central role in clearing amyloid-beta and tau, the hallmark proteins of AD. Despite rapid growth in this research area, no comprehensive bibliometric overview had previously mapped the field. This 2025 study fills that gap with systematic analysis of 595 peer-reviewed articles from the Web of Science Core Collection (2010–2025).

The most striking finding is the sheer pace of growth: 467 of the 595 total papers (78.49%) were published between 2020 and 2024, with annual output exceeding 100 articles in both 2023 and 2024. This represents exponential expansion triggered by the seminal 2012 Iliff et al. paper first demonstrating glymphatic function in rodents. A three-dimensional network analysis (country-institution-topic) confirmed that the United States dominates the collaborative landscape, with the University of Rochester and Maiken Nedergaard's lab (40 publications, most of any single author) as the undisputed central nodes. China ranked second in publication volume but with comparatively lower international citation impact, while Japan and Italy made notable contributions to CSF pathway dysfunction and cognitive impairment subfields.

Keyword co-occurrence and co-citation clustering using CiteSpace revealed three major thematic clusters defining the field. The first centers on glymphatic anatomy and mechanics: CSF-ISF exchange dynamics, AQP4 polarization at astrocytic endfeet, and perivascular space architecture. The second cluster addresses pathophysiological links: how glymphatic dysfunction accelerates amyloid-beta and tau deposition, the bidirectional relationship with sleep-wake cycles, and the accelerating effect of aging on clearance failure. Animal studies show that AQP4 knockout or aging-induced glymphatic impairment significantly accelerates Aβ plaque formation and induces hippocampal-dependent spatial memory deficits. The third cluster encompasses clinical translation: DTI-ALPS (diffusion tensor image analysis along the perivascular space) has emerged as a validated non-invasive imaging biomarker for glymphatic function in humans, with reduced DTI-ALPS indices correlating with lower CSF Aβ levels and worse cognitive scores in AD patients.

Co-citation analysis revealed that foundational papers by Iliff Jeffrey J. and Nedergaard Maiken continue to anchor the citation network, functioning as knowledge gatekeepers with high betweenness centrality scores. However, a clear temporal shift is visible: recent citation clusters concentrate on glymphatic function assessment technologies and cross-disease mechanistic investigations, signaling the field's maturation from basic discovery toward translational and clinical science. Burst detection analysis identified glymphatic imaging assessment and sleep-AD interaction mechanisms as the most rapidly accelerating current hotspots.

The study's authors highlight several key implications. The convergence of multimodal imaging (DTI-ALPS alongside PET amyloid/tau imaging), combined with mechanistic insights into AQP4 regulation and sleep optimization, could enable earlier AD detection and provide novel therapeutic targets before irreversible neuronal loss. The observation that immunotherapy trials (lecanemab, donanemab) show limited benefit may partly reflect insufficient baseline glymphatic clearance capacity, suggesting that enhancing glymphatic function could amplify the efficacy of existing treatments. Future research priorities identified include standardizing DTI-ALPS protocols, developing pharmacological AQP4 modulators, and designing clinical trials that combine sleep intervention with glymphatic function monitoring as an AD prevention strategy.